首页> 外国专利> B. Transformed T cells and T cell receptors for anticancer immunology

B. Transformed T cells and T cell receptors for anticancer immunology

机译:B.转化的T细胞和T细胞受体用于抗癌免疫学

摘要

T (TCR) cell receptors bind to tumor antigen (TAA) to metastasize to cancer cells.T cells representing these cellsProduction and treatment of cancer Especially,This note deals with TCR and its variability and peptide binding to HLA molecules of class I or II.For example, the amino acid sequence of MAG-003 is Kvlehvv (SEQ ID n 1). It also involves peptides.Protein.Nucleic acid and cells for immunotherapy. Especially,This description is related to immunotherapy for cancer. It also involves epithelioma of T-cell peptides associated with tumors.Individually or in combination with other cancer-related peptides may play a role.For instanceAs an active drug component in vaccine components, it can stimulate anti-tumor immune response or pre-stimulate living T cells and transfer them to patients. Peptides that bind to molecules in larger histocompatibility complexes.Or similar peptideThey may also be targets of antibodies.Receptors of T-soluble cells and other binding molecules.
机译:T(TCR)细胞受体与肿瘤抗原(TAA)结合并转移至癌细胞。代表这些细胞的T细胞产生和治疗癌症特别是,本说明涉及TCR及其与I或II类HLA分子的结合和可变性。例如,MAG-003的氨基酸序列是Kvlehvv(SEQ ID n 1)。它还涉及肽,蛋白质,核酸和用于免疫疗法的细胞。特别地,该描述与癌症的免疫疗法有关。它也涉及与肿瘤相关的T细胞肽的上皮瘤,可能单独或与其他与癌症相关的肽结合发挥作用,例如作为疫苗成分中的活性药物成分,它可以刺激抗肿瘤免疫反应或预先刺激活的T细胞并将其转移给患者。与较大的组织相容性复合物中的分子结合的肽或类似肽,它们也可能是抗体的靶标.T可溶性细胞和其他结合分子的受体。

著录项

  • 公开/公告号CO2018010811A2

    专利类型

  • 公开/公告日2018-10-22

    原文格式PDF

  • 申请/专利权人 IMMATICS BIOTECHNOLOGIES GMBH;

    申请/专利号CO20180010811

  • 申请日2018-10-09

  • 分类号C07K14/435;A61K35/12;A61K35/66;C12N15/09;C12N15/10;

  • 国家 CO

  • 入库时间 2022-08-21 12:53:07

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号